Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

Hepatology

Volumn 63, Issue 4, 2016, Pages 1357-1367

  Ponsioen, Cyriel Y ^a   Chapman, Roger W ^b   Chazouillères, Olivier ^c   Hirschfield, Gideon M ^d   Karlsen, Tom H ^e   Lohse, Ansgar W ^f   Pinzani, Massimo ^g   Schrumpf, Erik ^e   Trauner, Michael ^h   Gores, Gregory J ⁱ  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d University of Birmingham   (United Kingdom)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; BILIRUBIN; BIOLOGICAL MARKER; BUDESONIDE; COLCHICINE; DOCOSAHEXAENOIC ACID; HYALURONIC ACID; INFLIXIMAB; METRONIDAZOLE; MINOCYCLINE; MYCOPHENOLIC ACID; NICOTINE; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RIFAXIMIN; SILYMARIN; SIMTUZUMAB; TACROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASE 1; URSODEOXYCHOLIC ACID; VANCOMYCIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLANGIOGRAPHY; CLINICAL TRIAL (TOPIC); CONSENSUS; DISEASE COURSE; DISEASE MARKER; ELASTOGRAPHY; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAGNETIC RESONANCE CHOLANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSIENT ELASTOGRAPHY; CHOLANGITIS, SCLEROSING; END STAGE LIVER DISEASE; EVIDENCE BASED MEDICINE; FEMALE; INTERNATIONAL COOPERATION; LIVER TRANSPLANTATION; MALE; METABOLISM; MORTALITY; NEEDS ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROCEDURES; RARE DISEASE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

BIOMARKERS; CHOLANGITIS, SCLEROSING; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CONSENSUS; DISEASE PROGRESSION; END STAGE LIVER DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERNATIONALITY; LIVER TRANSPLANTATION; MALE; NEEDS ASSESSMENT; PRACTICE GUIDELINES AS TOPIC; RARE DISEASES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84961830162     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28256     Document Type: Article

References (61)

1. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-2055.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
3. Olsson R, Boberg KM, Schaffalitsky de Muckadell O, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
4. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-814.
5. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005;24:67-78.
6. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74:979-983.
7. van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-459.
8. Olsson R, Broomé U, Danielsson Å, Hagerstrand I, Järnerot G, Lööf L, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology. 1995;108:1199-1203.
9. Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-695.
10. Van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, Kuiper H, Nix GA, Becx MC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998;29:417-423.
11. Angulo P, Bharucha AE, Jorgensen RA, Desotel CK, Sandborn WJ, Larusso NF, et al. Oral nicotine in treatment of primary sclerosing cholangitis (a pilot study). Dig Dis Sci 1999;44:602-607.
12. van Milligen de Wit M, Kuiper H, Camoglio L, van Bracht J, Jones EA, Tytgat GN, van Deventer SJ. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? Eur J Gastroenterol Hepatol 1999;11:129-136.
13. Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, Meyer zum Buschenfelde KH, Lohse A. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primarysclerosing cholangitis. Ann Intern Med 1999;131:943-946.
14. Angulo P, Batts K, Jorgensen RA, Larusso N, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2333-2337.
15. Van Hoogstraten HJ, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol 2000;95:2015-2022.
16. Bharucha AE, Jorgensen R, JLichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for thetreatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2338-2342.
17. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol 2001;13:171-175.
18. Mitchell SA, Bansi DS, Hunt N, Bergmann KV, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
19. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-1562.
20. Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379-1386.
21. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005;100:308-312.
22. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007;27:451-453.
23. Vleggaar FP, Monkelbaan J, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008;20:688-692.
24. Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008;42:522-526.
25. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
26. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2007;53:1716-1720.
27. Silveira MG, Torok NJ, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009;104:83-88.
28. Martin CR, Blanco PG, Keach JC, Petz JL, Zaman MM, Bhaskar KR, et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2011;35:255-265.
29. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 2013;37:604-612.
30. Tabibian JH, Gossard AA, El-Youssef M, Eaton JE, Petz JL, Jorgensen RA, et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther 2014 Jun 9. doi: [Epub ahead of print]
31. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, et al. 24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-481.
32. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1005-1013.
33. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-990.
34. Stanich PP, Björnsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liv Dis 2011;43:309-313.
35. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013;58:329-334.
36. Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013;11:841-846.
37. Rupp C, Rössler A, Halibasic E, Sauer P, Weiss KH, Friedrich K, et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther 2014;40:1292-1301.
38. de Vries EM, Boonstra K, Leeflang M, Beuers U, Ponsioen CY. Normalization of alkaline phosphatase within the first year after diagnosis is of prognostic value in primary sclerosing cholangitis. Gastroenterology 2014;146(Suppl 1):S-907.
39. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011;140:1970-1979.e3.
40. Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, et al. Elastography are associated with severity of fibrosis and outcomes. Gastroenterology. 2014;146:970-979.
41. Wiesner RH, Grambsch PM, Rolland Dickson E. Primary sclerosing cholangitis: natural history, prognostic factors, and survival analysis. Hepatology 1989;10:430-436.
42. Olsson R, Hagerstrand I, Broomé U, Danielsson A. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995;48:933-935.
43. Angulo P, Larson D, Therneau T. Time course of histological progression in PSC. Am. J. Gastroenterol 1999;94:3310-3313.
44. de Vries EM, Verheij J, Hubscher SG, Leeflang MM, Boonstra K, Beuers U, Ponsioen CY. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. J Hepatol 2015;13:1212-1219.
45. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009;51:585-594.
46. Roselli M, MacNaughtan J, Jalan R, Pinzani M. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 2013;62:1-9.
47. Piccinino F, Sagnelli E, Pasquali G, Giusti G. Complications following percutaneous liver biopsy. J Hepatol 1986;2:165-173.
48. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:1-6.
49. Cadranel JF, Rufat P, Degos F; for the Group of Epidemiology of the French Association for the Study of the Liver. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 2000;32:477-481.
50. Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996;23:1079-1083.
51. Li QH. Evaluating co-primary endpoints collectively in clinical trials. Biomed J 2009;51:137-145.
52. Tischendorf JJ, Hecker H, Krüger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007;102:107-114.
53. Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2010;18:23-31.
54. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenetrology 2009;136:160-167.
55. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-1251.
56. Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology 2015;62:188-197.
57. Ponsioen C, Reitsma J, Boberg K, Aabakken L, Rauws E, Schrumpf E. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy 2010;42:742-747.
58. Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouillères O, Arrivé L. Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology 2013;59:242-250.
59. Nilsson H, Blomqvist L, Douglas L. Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Res Imaging 2014;39:879-886.
60. Prentice RL. Surrogate endpoints in clinical trials: definitions and operational criteria. Stat Med 1989;8:431-440.
61. Sanyal AJ, Friedman SL, McCullough AJ, Dimick L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases (AASLD)-U.S. Food and Drug Administration (FDA) joint workshop. Hepatology 2014;61:1392-1405.